Capstone Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-511
| Closed | -$391K | – | 1803 |
|
|
2025
Q4 | $394K | Buy |
+511
| New | +$347K | ﹤0.01% | 1230 |
|
|
2025
Q1 | – | Sell |
-5,301
| Closed | -$3.65M | – | 1781 |
|
|
2024
Q4 | $3.78M | Buy |
5,301
+4,343
| +453% | +$3.64M | 0.01% | 637 |
|
|
2024
Q3 | $1.01M | Sell |
958
-312
| -25% | -$347K | ﹤0.01% | 958 |
|
|
2024
Q2 | $1.33M | Sell |
1,270
-233
| -16% | -$226K | ﹤0.01% | 870 |
|
|
2024
Q1 | $1.45M | Buy |
1,503
+1,054
| +235% | +$1M | 0.01% | 948 |
|
|
2023
Q4 | $394K | Buy |
+449
| New | +$370K | ﹤0.01% | 1455 |
|
|
2023
Q3 | – | Sell |
-565
| Closed | -$444K | – | 2257 |
|
|
2023
Q2 | $406K | Buy |
+565
| New | +$436K | ﹤0.01% | 1246 |
|
|
2023
Q1 | – | Sell |
-54
| Closed | -$40.7K | – | 1659 |
|
|
2022
Q4 | $39K | Buy |
54
+6
| +13% | +$4.43K | ﹤0.01% | 1461 |
|
|
2022
Q3 | $33K | Buy |
48
+24
| +100% | +$15.1K | ﹤0.01% | 1621 |
|
|
2022
Q2 | $14K | Buy |
+24
| New | +$15.6K | ﹤0.01% | 1665 |
|
|
2021
Q2 | – | Sell |
-4,030
| Closed | -$2.04M | – | 1848 |
|
|
2021
Q1 | $1.91M | Sell |
4,030
-20,555
| -84% | -$10M | 0.01% | 951 |
|
|
2020
Q4 | $11.9M | Buy |
24,585
+15,596
| +174% | +$8.42M | 0.04% | 352 |
|
|
2020
Q3 | $5.03M | Buy |
8,989
+8,725
| +3,305% | +$5.29M | 0.03% | 514 |
|
|
2020
Q2 | $165K | Buy |
+264
| New | +$150K | ﹤0.01% | 1236 |
|
|
2020
Q1 | – | Sell |
-14,438
| Closed | -$5.96M | – | 1357 |
|
|
2019
Q4 | $5.42M | Sell |
14,438
-11,736
| -45% | -$3.95M | 0.03% | 530 |
|
|
2019
Q3 | $7.26M | Sell |
26,174
-6,512
| -20% | -$1.93M | 0.05% | 346 |
|
|
2019
Q2 | $10.2M | Buy |
32,686
+30,305
| +1,273% | +$10.1M | 0.07% | 282 |
|
|
2019
Q1 | $978K | Buy |
+2,381
| New | +$980K | 0.01% | 819 |
|
|
2018
Q4 | – | Sell |
-1,288
| Closed | -$471K | – | 1345 |
|
|
2018
Q3 | $520K | Buy |
+1,288
| New | +$490K | 0.01% | 784 |
|
|
2018
Q1 | – | Sell |
-1,096
| Closed | -$412K | – | 510 |
|
|
2017
Q4 | $412K | Buy |
1,096
+596
| +119% | +$241K | 0.01% | 305 |
|
|
2017
Q3 | $223K | Sell |
500
-400
| -44% | -$190K | 0.01% | 452 |
|
|
2017
Q2 | $442K | Buy |
+900
| New | +$394K | 0.01% | 431 |
|
|
2016
Q3 | – | Sell |
-10,303
| Closed | -$3.6M | – | 893 |
|
|
2016
Q2 | $3.6M | Buy |
+10,303
| New | +$3.97M | 0.07% | 170 |
|
|
2016
Q1 | – | Sell |
-400
| Closed | -$217K | – | 752 |
|
|
2015
Q4 | $217K | Sell |
400
-1,000
| -71% | -$542K | 0.01% | 426 |
|
|
2015
Q3 | $651K | Buy |
+1,400
| New | +$752K | 0.02% | 257 |
|
Other funds holding REGN
VCM
N
Capstone Investment Advisors's REGN Position: Q1 2026 in Review
Capstone Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 511 shares — an estimated $391K sold.
Capstone Investment Advisors first reported a position in REGN in Q3 2015 and held it in 25 quarters. The position peaked at $11.9M in Q4 2020. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Capstone Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Capstone Investment Advisors sold 511 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $391K.
- Capstone Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 25 quarters.
- Capstone Investment Advisors's Regeneron Pharmaceuticals position peaked at $11.9M in Q4 2020.
- 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.